SCH79797

SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes[1][2][3][4].

Product Specifications

CAS Number

[245520-69-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Protease Activated Receptor (PAR)

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein

Applications

Neuroscience-Neurodegeneration

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sch79797.html

Purity

99.74

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

NC1=NC(NC2CC2)=NC3=CC=C(N(CC4=CC=C(C(C)C)C=C4)C=C5)C5=C31

Molecular Formula

C23H25N5

Molecular Weight

371.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Ahn HS, et al. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4- (1-methylethyl) phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol. 2000 Nov 15;60 (10) :1425-34.|[2]Di Serio C, et al. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol. 2007 Jul;101 (1) :63-9.|[3]Sokolova E, et al. A novel therapeutic target in various lung diseases: airway proteases and protease-activated receptors. Pharmacol Ther. 2007 Jul;115 (1) :70-83.|[4]Strande JL, et al. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007 Jul;102 (4) :350-8.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

PAR1

Citation 01

Exp Mol Med. 2024 Dec;56 (12) :2631-2641.|J Appl Toxicol. 2025 Sep 1.|J Immunother Cancer. 2025 Jul 13;13 (7) :e010898.|Res Sq. 2024 Sep 04.|iScience. 2021 Oct 30;24 (11) :103386.